Medtronic MiniMed Recalled 116,645 Insulin Pumps Over Delivery Risk (2026)
Medtronic MiniMed recalled 116,645 MiniMed 640G insulin pumps worldwide, including the United States. The devices can deliver too much or too little insulin when the pump height changes relative to the infusion site due to gravity-driven pressure shifts. Stop using the pump immediately and contact Medtronic MiniMed or your healthcare provider for guidance.
Quick Facts at a Glance
Recall Date
February 13, 2026
Hazard Level
HIGH
Brand
Medtronic MiniMed
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL
Hazard Information
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
What You Should Do
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Medtronic MiniMed, Inc. or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
No spamUnsubscribe anytime
About This Product
Medtronic MiniMed insulin pumps are used by people with diabetes to continuously deliver insulin. These devices are part of a medical device ecosystem that combines hardware with monitoring and software to manage blood sugar.
Why This Is Dangerous
The infusion pump can mis-dose insulin when its height relative to the infusion site changes. This is due to gravity-driven pressure changes affecting how insulin is delivered.
Industry Context
This recall is not described as part of a broader industry pattern in the provided data.
Real-World Impact
Patients could experience severe blood sugar events requiring emergency care. The recall emphasizes immediate cessation of use and consultation with a clinician.
Practical Guidance
How to identify if yours is affected
Check model numbers on the device or accompanying materials for MMT-1711, MMT-1712, MMT-1751, or MMT-1752.
Confirm that the unit is a MiniMed infusion pump from the Paradigm, 600 series, or BLE 700 series.
Review the recall notification from Medtronic MiniMed and the FDA page for confirmation.
Where to find product info
Recall details and instructions are available on the FDA enforcement page and Medtronic’s recall communications.
What timeline to expect
Refunds or replacements are typically processed within weeks after verification, depending on the manufacturer's procedures.
If the manufacturer is unresponsive
Document all communications with the manufacturer.
File a formal complaint with consumer protection agencies if needed.
Consider consulting a healthcare provider for interim diabetes management guidance.
How to prevent similar issues
Regularly check for recalls on devices used for critical health management.
Stay enrolled in manufacturer recall notifications and review updated safety alerts.
Ask healthcare providers about safer, current-generation pump options when purchasing.
Documentation advice
Keep copies of recall notices, model numbers, purchase receipts, and all communications with the manufacturer and clinicians.
Product Details
Model numbers: MMT-1711, MMT-1712, MMT-1751, MMT-1752. Sold worldwide; US nationwide distribution. No specific sale dates or price information provided.
Reported Incidents
No injuries or incidents have been reported.
Key Facts
116,645 units recalled worldwide
Models: MMT-1711, MMT-1712, MMT-1751, MMT-1752
Hazard: unintended insulin over-delivery or under-delivery due to pump height relative to infusion
Distribution: Worldwide; US nationwide distribution listed
Remedy: Stop using the device; follow manufacturer recall instructions; contact Medtronic MiniMed
Medtronic recalled 453,144 MiniMed 780G insulin pumps worldwide after reports of unintended insulin delivery when the pump height changes relative to the infusion site. The defect stems from gravity-driven pressure changes affecting hydrostatic delivery. Patients and caregivers should stop using the devices immediately and follow the recall notice, contacting Medtronic MiniMed or their clinician’s
Medtronic recalled 13,429 MiniMed insulin pumps worldwide after identifying unintended insulin delivery errors. The issue occurs when the pump height relative to the infusion site changes, causing over-delivery or under-delivery of insulin. Patients should stop using the device and contact Medtronic for instructions.
Medtronic MiniMed recalled 24,946 MiniMed 740G insulin pumps worldwide after identifying unintended insulin delivery when the pump height changes relative to the infusion site. The defect can cause over-delivery or under-delivery of insulin due to gravity-driven pressure changes. Patients should stop using the device and contact Medtronic MiniMed for instructions on recall steps, refunds or a swap
Medtronic MiniMed recalled 26,647 Paradigm REAL-Time Revel insulin pumps distributed worldwide, including in the United States. A design flaw can cause insulin to be over- or under-delivered when the pump height changes relative to the infusion site. Patients and health providers should stop using the device immediately and follow the manufacturer’s recall instructions. The recall covers Paradigm,
Medtronic MiniMed recalled 37,458 insulin pumps sold worldwide through healthcare providers, including the MiniMed 720G, after finding that a pump raised above or lowered relative to the infusion site can deliver insulin too much or too little. The defect stems from changes in gravitational force affecting hydrostatic and hydrodynamic pressures at the infusion site. Patients should stop using the
Medtronic MiniMed recalls 55,724 Paradigm REAL-Time Veo insulin pumps distributed worldwide. The pumps can deliver too much insulin when raised or too little when lowered relative to the infusion site due to gravity-driven pressure changes. Patients should stop using the device and contact Medtronic MiniMed or their healthcare provider for instructions and refunds.
Medtronic MiniMed recalled 29,074 Paradigm Real-Time insulin pumps worldwide. The devices may deliver insulin improperly when the pump is elevated or lowered relative to the infusion site due to gravitational effects. Patients should stop using the pumps immediately and follow recall instructions from the manufacturer and their healthcare provider.
Medtronic MiniMed recalled 73,656 Paradigm insulin pumps sold worldwide, including broad U.S. distribution, after a risk of unintended insulin delivery. The issue affects Paradigm, 600-series and BLE 700-series pumps. It can cause life-threatening highs or lows in insulin delivery. Stop using the device and follow recall instructions immediately.